NASDAQ · Biotechnology

PALI (PALI) Stock

$1.96 +0.00% NASDAQ: PALI Healthcare

Valuation

MetricValue
Price$1.96
Market Cap$340.22M
P/E Ratio-6.27
P/B Ratio2.53
P/S Ratio0.00
EPS (TTM)$-0.30
52-Week High$2.86
52-Week Low$0.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-13.18%
ROA-12.69%
ROCE-13.95%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio26.80

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-42.0M$-16.0M$-13.0M$-15.0M$-18.0M
Net Profit$-27.0M$-14.0M$-12.0M$-14.0M$-17.0M
EPS$-2546.10$-16.53$-27.01$-10.19$-0.30
Op Margin——-5228.0%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.0M$16.0M$14.0M$11.0M$134.0M
Total Liabilities$5.0M$3.0M$3.0M$3.0M$5.0M
Cash$10.0M$12.0M$12.0M$10.0M$133.0M
Borrowings$0$0$0$0$0

Latest News

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum GlobeNewswire · Jul 10, 2026 PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? Stocktwits · Jun 29, 2026 Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study MT Newswires · Jun 29, 2026 Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis GlobeNewswire · Jun 29, 2026 Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors GlobeNewswire · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-13.0M$-11.0M$-12.0M$-11.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$2.0M$2.0M$2.0M$0
Net Cash Flow$10.0M$2.0M$0$-3.0M$124.0M
Free Cash Flow$-15.0M$-13.0M$-11.0M$-12.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-3.80%
Quick Ratio23.71
Interest Coverage—
Return 1Y65.57%
Return 3Y-93.74%
Return 5Y-99.93%

Ownership

Insiders Held1.64%
Institutions Held96.11%
Institutions Float Held97.70%
Institutional HolderSharesReport Date
Ameriprise Financial, Inc.11,510,3202026-03-31
B Group, Inc. 11,414,2852026-03-31
Janus Henderson Group PLC10,689,4522026-03-31
Octagon Capital Advisors LP10,276,3172026-03-31
Perceptive Advisors Llc8,928,1492026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASBP $7.26 +3.13% -0.74 $837601 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
BCTX $3.53 +1.73% -0.04 $6.65M 0.00%
CRIS $4.69 -4.09% -0.35 $9.14M 0.00%
CTXR $0.57 -9.81% -0.68 $6.37M 0.00%

About PALI

PALI is led by CEO J. D. Finley, employs 8 people, headquartered in US, publicly traded since 2007.

PALI stock trades at $1.96 with a market capitalization of $340.22M. The stock is valued at a price-to-earnings (P/E) ratio of -6.27, price-to-book of 2.53, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.53 and $2.86, and currently trades 31.5% below its 52-week high.

On profitability, PALI generates a return on equity (ROE) of -13.18%, return on capital employed of -13.95%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides